- Home
- AMAL vs XNCR Comparison
AMAL vs XNCR Comparison
Compare AMAL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | XNCR |
|---|---|---|
| Founded | 1923 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 881.9M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AMAL | XNCR |
|---|---|---|
| Price | $36.99 | $11.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $36.00 | $22.89 |
| AVG Volume (30 Days) | 132.0K | ★ 669.2K |
| Earning Date | 04-22-2026 | 05-22-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | $6.52 |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $25.13 | $6.92 |
| 52 Week High | $42.66 | $18.69 |
Technical Indicators
Market Signals| Indicator | AMAL | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 45.79 |
| Support Level | $36.59 | $10.92 |
| Resistance Level | $39.34 | $12.87 |
| Average True Range (ATR) | 1.24 | 0.77 |
| MACD | -0.26 | 0.03 |
| Stochastic Oscillator | 16.07 | 34.92 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.